Latest news with #AdaptHealthCorp
Yahoo
08-05-2025
- Business
- Yahoo
AdaptHealth Corp (AHCO) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic ...
The company reduced its full-year revenue expectations by $40 million and adjusted EBITDA expectations by $5 million due to the disposition of certain incontinence assets. Free cash flow was negative, and certain cash collections anticipated in the first quarter were pushed into the second quarter. Net revenue for the first quarter declined 1.8% compared to the prior year quarter, partly due to one less business day. AdaptHealth Corp ( NASDAQ:AHCO ) has a broad geographic footprint with over 660 locations, positioning it well to capture market share and lead the transformation of the home health industry. The company is on track to achieve its free cash flow guidance for the full year, with a significant improvement from negative $38.9 million in the prior year quarter to negative $0.1 million. AdaptHealth Corp ( NASDAQ:AHCO ) reduced its debt balance by $25 million in Q1, contributing to a total debt repayment of $195 million over the last five quarters. The Diabetes Health segment showed signs of recovery with sequential improvement in new starts and the best resupply attrition rate in two years. First quarter revenue exceeded the midpoint of guidance by $13.1 million, driven by strong performance in the Respiratory Health and Diabetes Health segments. Story Continues Q & A Highlights Q: Can you provide additional color on the improvements in the Diabetes business, particularly regarding growth in pumps and CGM? Also, is the guidance change only due to the incontinence asset sale? A: The guidance change is exclusively for the disposal of certain incontinence assets. Regarding diabetes, we saw positive movement in our pump business, showing growth over the first quarter of 2024. In CGMs, we experienced a second consecutive quarter of sequential growth in new starts, indicating a turnaround in the diabetes segment. - Jason Clemens, CFO Q: Regarding new starts in Sleep Health, is this a market issue or a market share issue? Are you losing share, and how do you plan to address it? A: Starts were slightly off, but it's not due to external factors. In certain geographies, we need to improve our setup speed and operations. We have detailed plans with our Commercial and operations teams to address these gaps, and we remain confident in our full-year guidance. - Jason Clemens, CFO Q: Can you clarify the impact of tariffs on your fiscal 2026 outlook, given recent developments? A: We are feeling better about our tariff exposure than we did previously. Many manufacturers received clarifications on their Nairobi classification, which may reduce our potential impact. We are not in a position to change our $10 million potential impact estimate for fiscal '26 yet, but the outlook is more positive. - Jason Clemens, CFO Q: There was a step-up in CapEx this quarter. Is this related to tariffs or increased demand? A: The increase in CapEx is due to outperformance in Respiratory Health, driven by increased sales during a heavy flu season. This is unrelated to tariffs and is a result of patient census growth in respiratory conditions. - Jason Clemens, CFO Q: Can you discuss the progress and future expectations for the One Adapt strategy? A: One Adapt focuses on leveraging our scale from past acquisitions to deliver operational efficiency and brand unity. We aim to simplify our entity structure and enhance our commercial team's reach to maximize patient access. This strategy is expected to drive growth in the back half of 2025 and into 2026. - Suzanne Foster, CEO For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
06-05-2025
- Business
- Yahoo
AdaptHealth (NASDAQ:AHCO) Posts Better-Than-Expected Sales In Q1, Stock Jumps 13.2%
Healthcare services provider AdaptHealth Corp. (NASDAQ:AHCO) beat Wall Street's revenue expectations in Q1 CY2025, but sales fell by 1.8% year on year to $777.9 million. On the other hand, the company's full-year revenue guidance of $3.25 billion at the midpoint came in 0.5% below analysts' estimates. Its GAAP loss of $0.05 per share was significantly below analysts' consensus estimates. Is now the time to buy AdaptHealth? Find out in our full research report. AdaptHealth (AHCO) Q1 CY2025 Highlights: Revenue: $777.9 million vs analyst estimates of $764.8 million (1.8% year-on-year decline, 1.7% beat) EPS (GAAP): -$0.05 vs analyst estimates of $0.03 (significant miss) Adjusted EBITDA: $127.9 million vs analyst estimates of $127.3 million (16.4% margin, in line) The company dropped its revenue guidance for the full year to $3.25 billion at the midpoint from $3.29 billion, a 1.2% decrease EBITDA guidance for the full year is $685 million at the midpoint, in line with analyst expectations Operating Margin: 3%, down from 6.4% in the same quarter last year Free Cash Flow was -$58,000 compared to -$38.86 million in the same quarter last year Market Capitalization: $1.17 billion 'Amid elevated uncertainty in the external environment, we at AdaptHealth have stayed the course, with a relentless focus on improving our business and providing exceptional service to the 4.2 million patients that depend on us,' said Suzanne Foster, Chief Executive Officer of AdaptHealth. Company Overview With a network of approximately 680 locations serving patients across all 50 states, AdaptHealth (NASDAQ:AHCO) provides home medical equipment, supplies, and related services to patients with chronic conditions like sleep apnea, diabetes, and respiratory disorders. Sales Growth Examining a company's long-term performance can provide clues about its quality. Any business can have short-term success, but a top-tier one grows for years. Thankfully, AdaptHealth's 40.1% annualized revenue growth over the last five years was incredible. Its growth beat the average healthcare company and shows its offerings resonate with customers. AdaptHealth Quarterly Revenue We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. AdaptHealth's recent performance shows its demand has slowed significantly as its annualized revenue growth of 3.9% over the last two years was well below its five-year trend. AdaptHealth Year-On-Year Revenue Growth This quarter, AdaptHealth's revenue fell by 1.8% year on year to $777.9 million but beat Wall Street's estimates by 1.7%.
Business Wire
21-04-2025
- Business
- Business Wire
AdaptHealth Corp. Announces First Quarter 2025 Earnings Release Date and Conference Call
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)-- AdaptHealth Corp. (NASDAQ: AHCO) ('AdaptHealth' or the 'Company'), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, will release its first quarter 2025 financial results before the opening of the financial markets on Tuesday, May 6, 2025. Management will host a teleconference at 8:30 a.m. ET to discuss the results and business activities with analysts and investors. Interested parties may participate in the call by dialing: (800) 343-5172 (Domestic) or (203) 518-9856 (International) When prompted, reference Conference ID: AHCO1Q25 Webcast registration: Click Here Following the live call, a replay will be available for six months on the Company's website, under "Investor Relations." About AdaptHealth Corp. AdaptHealth is a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services. The Company operates under four reportable segments that align with its product categories: (i) Sleep Health, (ii) Respiratory Health, (iii) Diabetes Health, and (iv) Wellness at Home. The Sleep Health segment provides sleep therapy equipment, supplies and related services (including CPAP and BiLevel services) to individuals for the treatment of obstructive sleep apnea. The Respiratory Health segment provides oxygen and home mechanical ventilation equipment and supplies and related chronic therapy services to individuals for the treatment of respiratory diseases, such as chronic obstructive pulmonary disease and chronic respiratory failure. The Diabetes Health segment provides medical devices, including continuous glucose monitors and insulin pumps, and related services to patients for the treatment of diabetes. The Wellness at Home segment provides home medical equipment and services to patients in their homes including those who have been discharged from acute care and other facilities. The segment tailors a service model to patients who are adjusting to new lifestyles or navigating complex disease states by providing essential medical supplies and durable medical equipment. The Company is proud to partner with an extensive and highly diversified network of referral sources, including acute care hospitals, sleep labs, pulmonologists, skilled nursing facilities, and clinics. AdaptHealth services beneficiaries of Medicare, Medicaid, and commercial insurance payors, reaching approximately 4.2 million patients annually in all 50 states through its network of approximately 660 locations in 47 states.
Yahoo
16-04-2025
- Business
- Yahoo
Investors three-year losses continue as AdaptHealth (NASDAQ:AHCO) dips a further 11% this week, earnings continue to decline
As an investor its worth striving to ensure your overall portfolio beats the market average. But its virtually certain that sometimes you will buy stocks that fall short of the market average returns. We regret to report that long term AdaptHealth Corp. (NASDAQ:AHCO) shareholders have had that experience, with the share price dropping 49% in three years, versus a market return of about 22%. The falls have accelerated recently, with the share price down 23% in the last three months. But this could be related to the weak market, which is down 11% in the same period. After losing 11% this past week, it's worth investigating the company's fundamentals to see what we can infer from past performance. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS). AdaptHealth became profitable within the last five years. That would generally be considered a positive, so we are surprised to see the share price is down. So given the share price is down it's worth checking some other metrics too. Revenue is actually up 8.1% over the three years, so the share price drop doesn't seem to hinge on revenue, either. It's probably worth investigating AdaptHealth further; while we may be missing something on this analysis, there might also be an opportunity. The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers). We know that AdaptHealth has improved its bottom line lately, but what does the future have in store? You can see what analysts are predicting for AdaptHealth in this interactive graph of future profit estimates. AdaptHealth shareholders are down 17% for the year, but the market itself is up 7.4%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 8% over the last half decade. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Take risks, for example - AdaptHealth has 2 warning signs (and 1 which is a bit unpleasant) we think you should know about. If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
